Daniel Ek’s body-scanning startup Neko Health raises another $700M

Neko Health raised a $700 million Series C, following its $260 million Series B in Jan 2025, to scale its proprietary body-scanning plus bloodwork health assessment platform. The company reports 100,000+ scans completed and 350,000+ registered for its waitlist/appointments, and is preparing its first U.S. location in New York. Co-development/use cases include body composition insights for gym users and integration with Apple Health data for clinicians.

Analysis

The public-equity winner here is AAPL, but not because this translates into near-term revenue. The mechanism is ecosystem gravity: any consumer health workflow that moves from novelty to repeated use strengthens the case for the iPhone/Watch stack as the default identity, consent, and longitudinal-data layer. That supports wearables attach and, more importantly, raises switching costs for users who start to treat Apple Health as a personal medical ledger.

The market should be careful not to overread the funding round as proof of demand. A private capital raise can validate investor appetite, but the real test is utilization economics: repeat scan frequency, conversion to follow-up care, and whether the model can scale without a disproportionate compliance and clinician-cost burden. The first U.S. location is the key 1-3 month catalyst; if it shows strong retention and low CAC, the category can expand. If not, this remains a well-funded niche.

The biggest second-order risk is trust. Biometric + lab data creates an unusually sensitive attack surface, so a breach or a single high-profile false negative/false positive could slow adoption for quarters. The consensus may also be underestimating how much this benefits cybersecurity and data-governance vendors more than healthcare itself; the more clinically relevant consumer scanning becomes, the more expensive privacy, audit, and identity controls get. SPOT is effectively a vanity read-through, not a cash-flow story.

Key Decisions for Investors

• Modestly long AAPL vs QQQ on pullbacks over the next 6-12 months; the thesis is that health-data stickiness quietly lifts services/wearables optionality. Falsify if the next 2 earnings prints show no improvement in Health/Watch engagement metrics.
• Do not trade SPOT on this headline; Daniel Ek's involvement is not an operating read-through, and any move would likely be sentiment-only.
• Set a watch item for AAPL WWDC / next iOS cycle: add to AAPL only if Apple deepens HealthKit/AI triage integration; fade any post-announcement pop if no product evidence appears.
• Monitor cybersecurity and healthcare-data governance names as a secondary beneficiary basket; if a breach or regulatory action hits the category, that would be the more tradable public-market catalyst than the startup itself.